‘Global Plasma Fractionation Market Set To Grow To $40bn By 2023’ says newly published Visiongain research

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Plasma Fractionation 2018-2028: Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia

In this report, we examined the global plasma fractionation market including the major submarkets by product, application, region and national market. The industry consists of a small number of high-capacity commercial fractionators with extensive multinational operations, and a large number of medium to small fractionators, which have lower outputs and exist primarily to serve national markets.

The lead analyst of the report commented “Aside from the growth in the scale of the industry, there has been an increasing sophistication in the processes that ensure the safety and quality of products; a greater use of chromatography in fractionation technologies; a concentration of the industry into fewer hands; and shifts in the patterns of clinical usage for the various plasma-fractionated products. The key drivers of demand for fractionation services have also changed over time as new plasma products have become commercially available and new indications for the use of plasma products have been identified and adopted.”

Leading companies featured in the report include

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever